Inhaler preference appeared to vary by age, with pDMI used by more patients aged 75 years and older, and DPI used by more patients aged 40 to 60 years. Patients with asthma and chronic obstructive ...

Independent management company, Trilogy Hotels is calling for greater investment in Western Sydney to support the influx of visitors expected to the region on completion of the Western Sydney ...

The study will evaluate the pharmacokinetics, safety and tolerability of the RespiRx ™ Nicotine Inhaler compared to ... dose-dependent pharmacokinetics, pulmonary delivery and was well ...

The decision makes Dupixent the first biologic medicine approved in the U.S. for COPD, a lung disease that makes it difficult to breathe and is typically treated with inhaled medicines. Regeneron ...

Nunes and Peña currently have one win each over the other in their rivalry, and Peña thinks the trilogy is essential. “I’m hoping Amanda will want to come out of retirement, and I’m betting she will ...

Other companies are rushing to the space with prospective COPD medicines. Two weeks ago, GSK reported that its respiratory blockbuster Nucala plus inhaled maintenance therapy lowered the rate of ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.

Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...

Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD ...